Hepatic Arterial Infusion of a Replication-selective Oncolytic Adenovirus (dl1520):
Phase II Viral, Immunologic, and Clinical Endpoints

Tony Reid, Eva Galanis, James Abbruzzese, Dan Sze, Lawrence M. Wein, James Andrews, Britta Randlev, Carla Heise, Margaret Uprichard, Michael Hatfield, Larry Rome, Joseph Rubin, and David Kirn

ABSTRACT

Replication-selective oncolytic adenoviruses are being developed for the treatment of cancer, but the safety and feasibility of repeated adenovirus delivery to tumors via the bloodstream was unknown, particularly in light of a patient death after hepatic artery infusion of a replication-defective adenovirus vector. We performed a Phase II trial of an oncolytic replication-selective adenovirus (dl1520, also known as Onyx-015) administered by hepatic artery infusion in patients with gastrointestinal carcinoma metastatic to the liver (n = 27). dl1520 was infused into the hepatic artery (2 × 10¹² particles) on days 1 and 8 as a single agent, and thereafter starting on day 22 in combination with i.v. 5-fluorouracil and leucovorin every 28 days. Repeated viral infusions were feasible, and no deaths occurred on study; reversible grade 3/4 hyperbilirubinemia occurred in 2 patients. Systemic inflammatory cytokine responses varied greatly between patients and even between cycles within a given patient. Proinflammatory cytokines [e.g., tumor necrosis factor, IFN-γ, and interleukin (IL) 6] typically rose within 3 h and were followed at 18 h by a rise in IL-10. However, in the single patient who suffered a severe but reversible systemic inflammatory response, a unique cytokine profile was detected: marked acute increases of IL-6 (20-fold higher than average for all of the patients) and inhibition of IL-10 production. Delayed secondary peaks of viremia were reproducibly detected 3–6 days after treatment, even in the presence of high level neutralizing antibody titers and antiviral cytokines. Mathematical modeling was used to calculate the number of virus particles produced and shed into the blood with each replication cycle. The combination of virotherapy and chemotherapy had antitumoral activity in some chemotherapy-resistant colorectal tumors. The intra-arterial infusion of oncolytic adenoviruses warrants additional study.

INTRODUCTION

Anticancer agents with novel mechanisms of action are needed. Viruses are being developed to treat cancer using two contrasting approaches. The initial approach of using replication-defective viruses as delivery agents for therapeutic genes to tumors has been limited by insufficient levels and distributions of gene expression (1, 2). A complementary strategy has now emerged to use replication-selective oncolytic viruses as therapeutic agents themselves (3–9). Superior efficacy may be achieved by combining these two strategies and arming replication-selective viruses with therapeutic transgenes (8, 10, 11). To date, the published clinical experience with these agents has been almost exclusively limited to intratumoral injection on Phase I and II studies. In addition, the well-publicized death of a patient on an adenoviral gene therapy trial for OTC deficiency at the University of Pennsylvania raised serious concerns about the safety of arterial adenovirus administration. As a result, numerous trials in the United States and Europe were put on hold (12–15). Data on the feasibility and safety of intra-arterial adenovirus administration is needed.

[Received 5/20/02; accepted 9/5/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom requests for reprints should be addressed, at Kirn Oncology Consulting, 444 LaVerne Avenue, Mill Valley, CA 94941.]
HEPATIC ARTERIAL ADMINISTRATION OF ADENOVIRUS

hepatic artery infusion have been developed for colorectal liver metastases (33). Treatment on the Phase 1 trial included two doses of dl1520 by hepatic artery infusion as a single agent (days 1 and 8 to determine single agent safety) followed by combination treatment with i.v. 5-FU2 and leucovorin (to determine safety and efficacy of the combination). Dose escalation was carried out from 2 × 1012 to 2 × 1013 particles. No dose-limiting toxicity was identified either as a single agent or with chemotherapy, so the maximum dose was defined as the maximum feasible dose (Ref. 32; n = 3 at maximum dose). We subsequently carried out a Phase II trial of hepatic arterial dl1520 (2 × 1013 particles) in combination with i.v. 5-FU and leucovorin in patients with gastrointestinal carcinoma metastatic to the liver.

MATERIALS AND METHODS

Objectives. The primary objectives of this study were as follows: (a) to determine the safety of repeated infusions of dl1520 into the hepatic artery, alone and in combination with i.v. 5-FU and leucovorin; (b) to determine the antitumoral efficacy of dl1520 infusions in combination with 5-FU and leucovorin (as above) on metastatic colorectal tumors within the liver, specifically in patients with colorectal tumors refractory to 5-FU and leucovorin; (c) to determine viral shedding into the blood over time after initial clearance (secondary viremia consistent with replication). Secondary objectives included the following: (a) to determine the pharmacokinetic profile of the virus in the venous circulation; and (b) to determine the humoral and cytokine-mediated immune responses to hepatic artery infusions of dl1520.

Eligibility Criteria. Inclusion criteria included the following: histologically or cytologically confirmed carcinoma of gastrointestinal origin; cancer that was not considered resectable for potential cure; confirmed hepatic artery perfusion of both liver lobes and >50% of all tumor masses); Karnofsky performance status of ≥70%; life expectancy of ≥3 months; ≥18 years of age; consent form for study participation signed; must have been using a reliable method of contraception if sexually active or of reproductive potential; creatinine <2.0 mg/dl; AST and ALT <3.0-fold upper limit of normal; total bilirubin <2.0 mg/dl; PT/INR <2.0 and PT within normal limits; and neutrophils >1,500/ml, hemoglobin >9 g/dl, and platelets >100,000/ml. Exclusion criteria were as follows: known chronic liver dysfunction before the development of metastatic cancer (e.g., cirrhosis, chronic hepatitis), which in the estimation of the Principal Investigator put the patient at high risk for liver complications; >50% liver replacement by tumor (estimated radiographically); history of esophageal variceal bleeding within the preceding 8 weeks; active infection, including documented HIV; any viral syndrome diagnosed within the previous 2 weeks; chemotherapy within the previous 3 weeks (6 weeks for nitrosoureas or mitomycin-C); radiotherapy to the target tumor site within the last 4 weeks; concomitant hematological malignancy; chronic immunosuppressive medication; pregnant or lactating females; prior participation in any research protocol that involved administration of adenovirus vectors; and treatment with any other investigational therapy within the last 4 weeks. Because no single gold-standard test for p53 function within a tumor existed, p53 tumor status did not affect enrollment. However, the p53 gene status of the tumor was assessed by gene sequencing when sufficient amounts of tissue could be obtained (exons 2–11).

Test Article. dl1520 (Onyx-015) is a chimeric human group C adenovirus (Ad2 and Ad5) that does not express the 55 kD product of the E1B gene; the virus was constructed in the laboratory of Barker and Berk (16). The virus contains a deletion between nucleotides 2496 and 3323 in the E1B region encoding the 55-kD protein. In addition, a C to T transition at position 2022 in E1B generates a stop codon at the third codon position of the protein. These alterations eliminate expression of the E1B 55-kD gene in dl1520-infected cells. dl1520 was grown and titered on the human embryonic kidney cell line HEK293 as described previously (19).

Treatment Schedule. The treatment schedule is summarized in Fig. 1. The safety of single agent dl1520 (2 × 1012 particles) administered via the hepatic artery was determined after single infusions on days 1 and 8 (cycles 1 and 2). Starting on day 22, treatment cycles were 28 days and consisted of dl1520 infusions followed by i.v. chemotherapy within 6 h after virus infusion (see below). After completion of cycle 4, up to four additional cycles were optional based on toxicity and tumor response (see below).

Treatment Procedures. A standard hepatic artery catheter was introduced via the femoral artery for the infusion, unless an indwelling hepatic arterial port was already in place. Patient treatment by percutaneous femoral artery catheterization was performed in interventional radiology suites. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance through a percutaneous femoral arterial approach. Patients were sedated with short-acting opiates and benzodiazepines as necessary for the procedure, and provided analgesics and antiemetics as necessary afterward. Patients underwent diagnostic hepatic arteriograms immediately before the initial virus solution infusion to define arterial anatomy and to confirm hepatic arterial supply to infrahepatic tumor(s). Images were obtained by digital subtraction angiography. The existence of anomalous arterial anatomy, which may occur in up to 40% of the normal patient population, was established and documented. If there was a single branched hepatic artery, the infusion was given into the proper hepatic artery (not the common). In the event of multiple arterial supply, the proportion of the liver supplied by each artery was estimated from the pretreatment CT scan and the arteriogram. After optimal positioning of the catheter to ensure minimal reflux into arterial branches not supplying the liver, a single infusion of 10 ml of viral solution was administered over ~5 min followed by a 10-ml normal saline flush given at the same rate and site. The total viral dose administered was specified for the cohort. When multiple hepatic arteries were identified, the total dose was divided and administered into each artery according to the proportion of the liver supplied by that artery to provide even and complete distribution throughout the entire liver. After completion of the infusion, the femoral catheter was removed.

Frozen vialed virus solution was warmed and diluted with normal saline to the appropriate titer for each patient dose level. Vials of ONX-015 were opened and diluted in biological safety level 2 cabinets. Virus was maintained at 2–8°C during dilution and handling, except for warning to room temperature immediately before administration. The virus solution was then additionally diluted to a final volume of 10 ml. Dilutions were performed immediately before tumor injection using plastic syringes. ONX-015 infusions were given via intra-arterial catheter over 3–5 min. This infusion was followed immediately by a 10-ml D5W/Electrolyte 48 solution flush given in identical fashion. Vital sign assessments were taken at baseline, at the conclusion of the infusion, and then every 30 min for a total of 2 h. Patients were observed overnight in the hospital after injection at the discretion of the Principal Investigator.

For cycles 3 and 4 (starting on days 22 and 50), chemotherapy was given for 5 consecutive days starting within 6 h after the dl1520 infusion. Leucovorin (LCV) 20 mg/m2 i.v. was followed by 5-FU 425 mg/m2/day by i.v. bolus. Chemotherapy dose modifications because of toxicity were made according to

(Study day) Pre 1 4 8 22 50 78+

Treatment

- ONX-015 h.a.i.
- 5-FU/leucovorin i.v.

Assessment

- Pharmacokinetics
- Viral replication, shedding
- Cytokine assessment
- Neutralizing antibodies
- Efficacy (CT scan, serologic)

Fig. 1. Treatment and assessment schema. The treatment and assessment schema is outlined below by study day. h.a.i., hepatic artery infusion; pre, pretreatment; *, day 4 assessment of replication and shedding was based on quantitative PCR of the blood (genomes/ml) ~72 h (± 24 h) after the first injection. Patients with evidence of antitumoral activity on day 78 were eligible to continue treatment every 28 days for up to four additional cycles (day 78+).

2 The abbreviations used are: 5-FU, 5-fluorouracil; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; PTT, partial thromboplastin time; IL, interleukin; TNF, tumor necrosis factor; CT, computed tomography; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CEA, carcinoembryonic antigen; OTC, ornithine transcarbamylase; ARDS, adult respiratory distress syndrome.
guidelines at each study center. Up to four additional cycles of combination 
dl1520 and chemotherapy were allowable if treatment was well tolerated and  
symptomatic tumor progression had not been documented.

Toxicity Assessment on Study. The schedule of activities for patients on  
study is outlined in Fig. 1. Blood was drawn on day 8 of each cycle for serum  
chemistry, complete blood count, PT/PTT, liver function tests (AST, ALT,  
total and direct bilirubin, and alkaline phosphatase), and lactate dehydro-  
genase. Toxicity, including reports of adverse events, was assessed throughout  
treatment and for at least 28 days after treatment completion. The NCIC-  
Common Toxicity Criteria were used to categorize and grade toxicities.

Quantitative PCR Testing of Blood for Viral Genomes. The first  
five patients had pharmacokinetic blood draws taken on cycle 1 (day 1) and cycle  
3 (day 22) at the following time points after dl1520 infusion: 5, 10, 30, 60,  
90, 120, 180, and 360 min. Plasma was tested for virus by quantitative PCR. Blood  
was tested for the presence of dl1520 by quantitative PCR on day 1 (pharma-  
cokinetically drawn, described above) and on day 4 (±1) of cycle 1 in patients  
consenting to this extra blood draw. PCR for dl1520 was performed using the  
TaqMan assay, which quantitates the number of ONYX-015 genomes in  
human plasma (the amplicon overlaps the E1B region deletion and does not  
detect wild-type adenovirus sequences). PCR details are available (35). In  
brief, viral DNA is extracted from patient samples, standards, and controls  
using QIAmp DNA mini kit. The lower limit of detection is 1.05 × 10^4  
particles of ONYX-015 per ml of plasma. The presence of PCR inhibitors in  
the sample is monitored using an independent PCR reaction.

Mathematical Modeling of Viral Replication and Shedding into the  
Blood. The following data were used to calculate the estimated number of  
viral genomes produced and shed into the blood on cycle 4 in patient 3016:  
viral load was below the level of detection at 24 h after infusion (<10^3  
particles/ml); 10^3 particles/ml at 48 h; 1.5 × 10^4 particles/ml at 72 h; 4 × 10^4  
particles/ml at 96 h; below the level of detection at 120 h. We broke time into  
three periods: 0–48, 48–72, and >72 h. From 0–48 h, we assume the virus  
grows exponentially starting at v0 = 1 ml. Similarly for t >72 h, we assume  
the virus decays exponentially; note that v24 = 2859 g/ml, which is less  
than the limit of detection and, therefore, is consistent with the data. From  
48–72 h, we fit a smooth function, using the values and derivatives (from the  
exponential functions) at 48 and 72 h. This gives us four pieces of data  
allowing us to uniquely fit the cubic equation v(t) = at^3 + bt^2 + ct + d. The  
resulting function is v(t) = [(1/4)t^3 + (49/2)t^2 + (283/4)t − (129/2); all times  
10^3]. The clearance rate from t = 12 min (see pharmacokinetic results) is  
(ln2/0.2)/h.

Neutralizing Antibody Level Assessment. Neutralizing antibodies to  
dl1520 were assessed at baseline, day 22, and day 50. Titers against dl1520  
determined on blood samples as follows. Patient and control samples  
determined previously to produce high, midrange, and negative titers  
were assayed at baseline, day 22, and day 50. Titers against  
onyx-015 were assessed: IL-1, -6, -10, TNF, and IFN-  

RESULTS

Baseline Patient Characteristics. Baseline patient characteristics  
are described in Table 1. The tumor type was colorectal in 88% and  
pancreatic in 12%. The median age of patients on study was 59 years  
(range, 39–78), and 28% were female. Prior chemotherapy had  
been received in 88% of patients. Most patients had a Karnofsky  
Performance Status (KPS) of 90–100%. p53 gene status of the tumor  
could be obtained in approximately half of patients; 7 tumors had  
mutant sequences and 7 had wild-type gene sequences (exons 2–11).

Treatment Characteristics. Twenty-five patients received at least  
one cycle of dl1520. Eighteen patients subsequently received at least

| Table 1 Baseline patient characteristics by dose group (n = 27) |
|-----------------|-----------------|
| Age (years)     | Mean ± SD       |
| Median          | 59.0 ± 10.06    |
| Range           | 39–78           |
| Gender          |                 |
| Female          | 8 (30%)         |
| Male            | 19 (70%)        |
| Baseline KPS    |                 |
| 100             | 14 (52%)        |
| 90              | 3 (11%)         |
| 80              | 8 (30%)         |
| 70              | 2 (7%)          |
| 60              | 0               |
| Unknown         | 0               |
| Ethnic group    |                 |
| Black           | 24 (89%)        |
| Asian           | 3 (11%)         |
| Other           | 0               |
| Prior therapy   |                 |
| Surgery and chemo| 19 (70%)      |
| Surgery alone   | 3 (11%)         |
| Chemo alone     | 1 (4%)          |
| Surgery/chemo/other | 4 (15%)   |
| Colorectal histology | 24 (89%) |
| Yes             | No              |
| No              | 3 (11%)         |
| Months since diagnosis of liver metastases | Median 15.2 |
| Total bilirubin (baseline) | Range 0.03–53.09 |
| <0.7            | 11 (44%)        |
| Tumor area (baseline) | Median 48.8 |
| Range           | 5.6–385.6       |
one cycle of dl1520 plus 5-FU and leucovorin (mean 2.9 ± 1.65; median three cycles, maximum six).

**Viral Pharmacokinetics.** Quantitative PCR testing of the blood for ONYX-015 was performed at predetermined time points over the first 6 h after injection on cycles 1 and 3 (n = 5 patients; Fig. 2). The virus was rapidly cleared from the blood over 6 h. The pharmacokinetic parameters were nearly identical during cycles 1 and 3 (after high-level antibody titer increases): t1/2 α (10 versus 14 min, respectively) and t1/2 β (113 versus 135 min, respectively) were therefore not demonstrably affected by neutralizing antibody levels.

**Adverse Events.** dl1520 was generally well tolerated both as a single agent (cycles 1 and 2) and in combination with 5-FU/LV (cycles 3 and higher). No deaths occurred on study; after withdrawal from study, patients have died only as a result of tumor progression. Adverse events during cycles 1 and 2 of dl1520 (single agent) are reported by grade in Table 2. Nearly all of the patients reported flu-like symptoms, including fever, myalgias, asthenia, and/or chills. Chills, myalgias, and flu-like symptoms were mild to moderate (grade 1–2) in most cases, and the duration of these symptoms was typically short (<72 h). Cyclical fevers occurred in some patients at a period of ~72 h. No patients discontinued therapy on the basis of flu-like symptoms. A detailed description of chemotherapy-related toxicity will be the subject of another manuscript. The frequency and severity of chemotherapy-related toxicities were within the range expected when these agents are administered without dl1520.

No treatment-emergent clinical hepatotoxicity occurred during treatment, despite preexisting liver abnormalities because of intrahepatic metastases in more than half of the patients at baseline. Transient grade 1–2 hyperbilirubinemia was detected in approximately one-third of patients. In addition, two patients with grade 1–2 hyperbilirubinemia before treatment experienced reversible grade 3/4 hyperbilirubinemia categorized as “probably” or “definitely” related to the virus. The liver toxicity resolved within 7–10 days. These patients received two or more additional cycles without complication. Transient low-grade (1–2) transaminisitis was documented in several patients (after single agent virus) and was classified by the investigator as “possibly attributable” to dl1520; the laboratory abnormalities resolved within 7–12 days and did not reoccur after subsequent treatments. In light of the treatment-associated death because of ARDS on trial with a replication-defective adenovirus in a patient with OTC deficiency, it is notable that no coagulation abnormalities/disseminated intravascular coagulation were noted in any patients.

A single patient developed a systemic inflammatory reaction after treatment with cycle 4. This patient had tolerated three previous cycles of therapy without significant toxicity. Within the first 48 h after cycle 4 the patient developed a temperature of 104°F along with a significant lactic acidosis and localized vascular leak at sites of metastases in the chest. Within 5 days after treatment the patient was back to clinical and laboratory baseline, and was discharged soon thereafter without long-term sequelae. The patient serum cytokine profile after this cycle of treatment was highly unusual compared with cycles 3 or 4 for other patients (Fig. 5; P < 0.001 for baseline versus 3 h and/or 18 h) and to cycle 1 for this patient (Fig. 6).

**Viral Genomes in Blood after Initial Clearance.** Quantitative PCR of the blood was performed on day 1 (6 or 24 h) and on day 4 (±1) to assess viremia and surrogate evidence suggestive of viral replication. The genomes of virus per ml of plasma were determined by quantitative-PCR. C, genomes/ml in plasma for all patients with samples tested between 6 h and 96 h after virus infusion (pooled data on 7 patients).

![Fig. 2. Pharmacokinetics, clearance, and reappearance of ONYX-015 in plasma after hepatic arterial infusion.](image)

*Hyperbilirubinemia was caused by intrahepatic tumor progression in two of these cases; in 1 patient the adverse event was categorized as “definitely” related. The bilirubin in this patient decreased back down to grade one within 7–10 days on both cycles 1 and 2.*

<p>| Table 2 Incidence of adverse events by toxicity grade for cycles 1 and 2: dl1520 alone (±18% incidence) |
|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|</p>
<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Mild/moderate</th>
<th>Severe</th>
<th>Life-threatening</th>
<th>Fatal</th>
<th>Unknown</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>22</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>25</td>
</tr>
<tr>
<td>Chills</td>
<td>19</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>Alkaline phosphate increase</td>
<td>13</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>AST increased</td>
<td>13</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>Nausea</td>
<td>12</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>8</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>LDH increased</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>11</td>
</tr>
<tr>
<td>Bilirubinemia</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>ALT increased</td>
<td>8</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>7</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>7</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Asthenia</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Hypochromic anemia</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Granulocytosis</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Vomiting</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Myalgia</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Anemia</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
</tbody>
</table>

*Hyperbilirubinemia was caused by intrahepatic tumor progression in two of these cases; in 1 patient the adverse event was categorized as “definitely” related. The bilirubin in this patient decreased back down to grade one within 7–10 days on both cycles 1 and 2.*
replication (Fig. 3). Input virus was rapidly cleared within 6 h after the infusion to levels at or below the level of detection (<10^5 genomes/ml) in all 7 of the patients. Of these seven patients, 5 had viremia on day 4-5 at levels 17-400-fold greater than the limit of detection (Fig. 3; P < 0.001 for 6 versus 72 h). All 5 of the patients had colorectal carcinomas.

One patient had blood samples obtained daily after the cycle 4 infusion for 9 days (Fig. 4). Two cycles of viral shedding are demonstrated; interestingly, this is despite high level neutralizing antibodies and antiviral cytokines. Mathematical modeling of the viral replication cycle allowed calculations of the estimated peak concentrations of viral genomes and antiviral cytokines. Mathematical modeling of the viral replication cycle allowed calculations of the estimated peak concentrations of viral genomes/ml estimated to occur at 60 h after infusion; the area under the curve for the first cycle of treatment (median 3.2 x 10^7 genomes/ml x days; and the total number of viral genomes produced, shed into, and detected within the blood during the replication cycle = 1.3 x 10^11 genomes. Of note, the estimated number of genomes produced and shed is a fraction of the total virus produced within the tumor and, therefore, this is a determination of the minimum amount produced.

Immune Response. Neutralizing antibody titers to dl1520 (Ad5 protein coat) were positive in ~50% of patients before treatment. Titers increased and/or became positive in all of the patients after intravascular administration with dl1520. The median antibody titer after a single cycle was ~1:10,000. Titers continued to rise after a second cycle of treatment (median ~1:25,000).

Acute inflammatory cytokine expression was assessed in circulating WBCs (RNA expression) and serum (ELISA) of 9 patients at baseline, 3 h and 18 h after treatment cycles (Fig. 5). The following cytokines were measured: TNF, IFN-γ, IL-1, -6, and -10. IL-1 levels were not detectable at baseline, rose significantly by 3 h, and returned to near baseline by 18 h. TNF, IL-6, and IFN-γ all increased markedly by 3 h after treatment. Levels decreased between 3 and 18 h, but remained above baseline in most patients. The magnitude of changes in cytokine levels varied greatly between individual patients (Fig. 5) and from cycle to cycle in a given patient (Fig. 6).

Antitumoral Activity. Antitumoral activity was demonstrated with dl1520 in combination with 5-FU and leucovorin (Fig. 7). Overall tumor responses were as follows: 3 PR (11%), 4 MR (15%), 9 SD (33%), and 11 PD (41%). The antitumoral effects of dl1520 cannot be adequately assessed in patients who had not received previously this chemotherapy regimen; responses are conceivably because of chemotherapy alone. However, the three minor responses (30-48% shrinkage) in 5-FU/LCV-refractory patients are evidence for dl1520-associated antitumoral activity. Patient 3013 presented with a rapidly progressive CEA level and 5-FU-refractory colon cancer within the liver after three prior 5-FU-based chemotherapy regimens, including bolus and continuous infusions of 5-FU. After two cycles of single agent dl1520, the CEA continued to increase (from 350 to 450). After the second cycle of combination treatment with dl1520 plus 5-FU/leucovorin (cycle 4), a sudden spike in the CEA level was demonstrated from 450 to 750 over several days; a significant increase in intratumoral necrosis was noted on CT scan at this time. The CEA subsequently decreased significantly over time down to 77 ng/ml (83% reduction) over ~20 weeks (Fig. 7G). An interim CT scan demonstrated significant shrinkage (~30%), but unfortunately the patient refused a CT scan after combination therapy, so the final radiographic response is not known. A second 5-FU-refractory patient had PD on virus alone, followed by significant shrinkage on combination therapy. Tumor shrinkage was 35% from baseline and 50% from the time of combination therapy initiation.

Predictors of antitumoral efficacy cannot be definitively assessed in a study of this size with different tumor histologies, differing pretreatment characteristics, and varied prior treatments. However, several observations were of note and may generate hypotheses to be tested in

Fig. 3. Viral genomes shed into the blood. Quantitative PCR of the plasma was performed for quantification of Onyx-015 (genomes/ml) on day 1 (0.5-6 h after treatment) and on day 3 (72 h after treatment) of cycle 1 (n = 4 patients with multiple samples tested). After Onyx-015 clearance from the blood within the first 6 h after infusion (A-D), viral genomes are detectable again at 72 h in 3 of 4 patients at levels that are 18-396-fold above the lower limit of detection for the assay (A-C).
future trials. Of the 3 patients with 5-FU-refractory tumors who had minor responses to 5-FU plus \textit{dl1520}, all had delayed viremia. Two were \textit{p53} gene sequence mutant and one was \textit{p53} wild-type. The neutralizing antibody titers were positive (\textit{H11022} 1:20) at baseline in 2 of the 3 patients (approximately 1:10,000–1:30,000), and all 3 were positive after cycles 1 and 2.

**DISCUSSION**

We performed a Phase II trial of the replication-selective adenovirus \textit{dl1520} administered by hepatic arterial infusion, in combination with i.v. 5-FU and leucovorin, in patients with liver metastases from gastrointestinal (primarily colorectal) carcinomas. This is the first Phase II trial describing the intravascular administration of genetically engineered, replication-selective virus in patients. This study has major implications regarding the safety and feasibility of adenovirus administration into the blood, and into the hepatic artery specifically. This is particularly true given the report of a patient death after the hepatic artery administration of a replication-incompetent adenovirus into the hepatic artery for OTC deficiency. We report here that adenovirus administration into the blood can be performed with acceptable toxicity in patients with metastatic cancer. Importantly, the virus was well tolerated at doses that resulted in significant cyclical/
recurrrent viremia consistent with viral replication, proinflammatory cytokine induction, and evidence for chemosensitization of refractory tumors.

Concerns were raised about the safety of hepatic arterial adenovirus after the patient death on a clinical trial for patients with OTC deficiency (12–15). This patient received a dose of $\sim 4 \times 10^{13}$ particles with a replication-deficient adenovirus expressing the OTC gene. By report, in $<24$ h the patient experienced hyperammonemia, ARDS, and disseminated intravascular coagulation; this was followed over the next few days by multiorgan system failure and death (12).

These complications were not encountered on this study. Despite being well tolerated overall in the vast majority of patients, significant idiosyncratic toxic events did occur in several patients. Of note, reversible grade 3/4 hyperbilirubinemia (direct) attributable to virus treatment occurred in 2 patients. In addition, reversible grade 4 dyspnea occurred in 1 patient with a systemic proinflammatory response associated with profound lactic acidosis and peritumoral vascular leak; this event was associated with extreme elevations of IL-6 and undetectable IL-10 within the first 18 h after cycle 4 (see below). Although liver toxicity was dose-limiting in mice (32), liver toxicity...
Fig. 7. Early and delayed radiographic and tumor marker changes in patients with metastatic colon cancer. Serial contrast-enhanced CT scans at the level of the left portal vein from 3 patients are shown. Patient 3006 had previously untreated metastatic colon cancer to the liver at the time of study entry (A). After two cycles of single agent dl1520 the tumor masses were notable for acute swelling (B). After combination treatment with dl1520 plus chemotherapy (C), the overall tumor cross-section has decreased by >50% and the vascularity of the residual masses is markedly reduced (consistent with necrosis). Patient 3005 had metastatic colon cancer that was treated previously with three cycles of 5-FU/leucovorin. Nine months later the patient presented with tumor progression (D). After two cycles of single agent dl1520 (E), the largest tumor mass was notable for acute swelling and decreased vascularity (consistent with necrosis). After combination treatment with dl1520 plus 5-FU/leucovorin (F), near complete disappearance of the tumor masses was demonstrated. G, patient 3013 presented with a rapidly progressive CEA level and 5-FU-refractory colon cancer within the liver after three prior 5-FU-based chemotherapy regimens, including bolus and continuous infusions of 5-FU. After two cycles of single agent dl1520, the CEA continued to increase (downward arrows delineate treatment cycles). After the second cycle of combination treatment with dl1520 plus 5-FU/leucovorin (fourth arrow), a sudden spike in the CEA level was demonstrated; a significant increase in intratumoral necrosis was noted on CT scan at this time. The CEA subsequently decreased significantly over time. Significant necrosis and tumor shrinkage was noted on CT scan during this interval.
did not lead to treatment discontinuation in patients at this dose despite replacement of up to 50% of patient liver by tumor. In addition to the 2 cases of hyperbilirubinemia described above, transient mild to moderate transaminitis was documented in approximately one-third of patients. No disseminated intravascular coagulation was detected at the time points assessed. Mild to moderate fever and rigors were the most common adverse events; these were transient and did not lead to treatment discontinuation. Therefore, given that these patients had terminal cancer, hepatic arterial infusion of this E1B-55kD gene-deleted adenovirus was associated with acceptable toxicity both as a single agent and in combination with 5-FU-based chemotherapy.

Several aspects of the single idiosyncratic systemic proinflammatory response to a virus infusion are worth discussing. First, this patient had tolerated three prior infusions of dl1520 without significant toxicity. However, after cycle 4 the patient developed localized vascular leak at the site of metastatic tumors in the chest. This reaction was associated with an increased temperature and respiratory rate, decreased serum HCO3− and an elevated lactic acid. Despite high level proinflammatory cytokines, viral shedding into the bloodstream consistent with replication was detectable. This patient had markedly elevated levels of IL-6 acutely compared with all of the other patients (20-fold higher than average) and compared with levels after his first three treatment cycles. In addition, unlike all of the other patients and/or treatment cycles, his IL-10 levels decreased after cycle 4 acutely and were undetectable after 18 h. Therefore, this reaction could not have been predicted. It is possible that such a reaction contributed to the patient death on the OTC trial. Future studies may define predictive factors that can be used to either avoid treating high-risk patients or to identify them soon after treatment (e.g., by measuring their cytokine response) and thus allow rapid intervention.

Several important differences exist between this trial and the OTC trial. First, the viral dose tested on this study was ~10-fold lower. However, viral replication on this study almost certainly led to longer-term adenoviral exposure and shedding into the bloodstream than on the OTC trial with a replication-deficient adenovirus. In addition, 5 patients on a separate trial have now been treated i.v. with dl1520 at doses of 2 × 10^12 to 2 × 10^13 particles (35); these doses are up to 10-fold higher than on this trial and are close to those used before the fatal event in the OTC trial. None of the complications that occurred in the OTC patient occurred in these patients. It is probable that OTC patients have a greater sensitivity to viral exposure and any ensuing systemic inflammatory reaction than did the patients on this trial. Patients with OTC deficiency have a heightened sensitivity to viral and bacterial infections compared with the general population, and hyperammonemia, ARDS, and death can result (36). A proinflammatory reaction such as was demonstrated on this trial might not be tolerated in OTC patients. Of note, the protein coats of the viral particles were identical on these two studies. On the basis of this study, it is clear that adenoviruses, including replication-selective adenoviruses, can be administered into the bloodstream, and in particular into the hepatic artery, with toxicity that is acceptable in cancer patients. Future trials of intravascular adenovirus in patients with advanced, refractory cancers are indicated.

This study is the first to clearly report data consistent with the replication of a therapeutic virus after intra-arterial administration in humans. The virus was cleared rapidly from the peripheral blood (half-life ~12 min); by 6 h, patients had blood levels at or below the limit of detection for the assay (~10^4 genomes/ml). Viral replication was then assessed by after the viral concentration in plasma over time. Previous clinical trials have demonstrated a strong correlation between in situ evidence of replication and detectable viral genomes in the blood at the same time (3). However, posttreatment tumor biopsies
profile in combination with chemotherapy. This opens up the possibility of treating many tumors using this approach. The chemosensitization demonstrated by \textit{dil520} on trials of head and neck cancer patients has now been documented with another tumor type and another route of administration. In addition, based on these clinical results, clinical testing of replication-selective adenoviruses as i.v. therapies for metastatic tumors is feasible; a Phase I trial has been completed recently (35). To achieve equivalent levels of virus within tumors using the i.v. route, however, higher doses may be necessary. Neutralizing antibodies will almost certainly play a larger role after i.v. administration, and novel methods to inhibit antibody production may be needed.

ACKNOWLEDGMENTS

We thank the following individuals for their assistance: Len Post, Scott Freeman, Larry Romel, Sherry Toney, Amy Waterhouse, Patrick Trown, Deborah Hahn, Ellen Morgan, Phil Custodio, and Fran Kahan. We would also thank Frank McCormick for his thoughtful insights that led to this project being initiated.

REFERENCES

6. Hawkins, L., Nye, J., Castro, D., Johnson, L., Kirn, D., and Hermiston, T. Replicating adenovirus demonstrated by neutralizing antibodies will almost certainly play a larger role after i.v. administration, and novel methods to inhibit antibody production may be needed.

ACKNOWLEDGMENTS

We thank the following individuals for their assistance: Len Post, Scott Freeman, Larry Romel, Sherry Toney, Amy Waterhouse, Patrick Trown, Deborah Hahn, Ellen Morgan, Phil Custodio, and Fran Kahan. We would also thank Frank McCormick for his thoughtful insights that led to this project being initiated.

REFERENCES

6. Hawkins, L., Nye, J., Castro, D., Johnson, L., Kirn, D., and Hermiston, T. Replicating adenovirus demonstrated by neutralizing antibodies will almost certainly play a larger role after i.v. administration, and novel methods to inhibit antibody production may be needed.